Mesenchymal stem cell-based COVID-19 therapy: Bioengineering perspectives
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2022Yazar
Karakaş, NihalÜçüncüoğlu, Süleyman
Uludağ, Damla
Karaoğlan, Birnur Sinem
Shah, Khalid
Öztürk, Gürkan
Üst veri
Tüm öğe kaydını gösterKünye
Karakaş, N., Üçüncüoğlu, S., Uludağ, D., Karaoğlan, B. S., Shah, K. ve Öztürk, G. (2022). Mesenchymal stem cell-based COVID-19 therapy: Bioengineering perspectives. Cells, 11(3). https://doi.org/10.3390/cells11030465Özet
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Mesenchymal stem cells (MSCs) are currently utilized in clinics for pulmonary inflammatory diseases, including acute respiratory distress syndrome and acute lung injury. Given that MSCs offer a promising treatment against COVID-19, they are being used against COVID-19 in more than 70 clinical trials with promising findings. Genetically engineered MSCs offer promising therapeutic options in pulmonary diseases. However, their potential has not been explored yet. In this review, we provide perspectives on the functionally modified MSCs that can be developed and harnessed for COVID-19 therapy. Options to manage the SARS-CoV-2 infection and its variants using various bioengineering tools to increase the therapeutic efficacy of MSCs are highlighted.
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
CellsCilt
11Sayı
3Koleksiyonlar
- Diğer Yayınlar Koleksiyonu [258]
- Makale Koleksiyonu [302]
- Makale Koleksiyonu [3790]
- Makale Koleksiyonu [358]
- Makale Koleksiyonu [188]
- PubMed İndeksli Yayınlar Koleksiyonu [4251]
- Scopus İndeksli Yayınlar Koleksiyonu [6601]
- WoS İndeksli Yayınlar Koleksiyonu [6677]